Navigation Links
Novel therapy may prove effective in treatment of 30 percent of cancers
Date:5/13/2009

A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.

The study, inspired by the exciting discoveries made by Dr. Borden at IRIC, was a joint project between her research group, who monitored molecular events in trial patients, and Dr. Sarit Assouline of the Segal Cancer Centre, Jewish General Hospital, who led the clinical part of the trial.

The integration of these two teams made it possible to rapidly move from a research lab to patient tests. The study team targeted the gene by giving trial participants a mimic of its natural target, ribavirin. "Our results are the first to show that targeting eIF4E in humans is clinically beneficial," explains Dr. Borden. "We also found that ribavirin not only blocks eIF4E, it has no side effect on patients."

The trial studied patients with M4/M5 acute myeloid leukemia who had undergone several other treatments that had previously failed. "We had striking clinical improvements with even partial and complete remissions," indicated Assouline.

Dr. Wilson Miller, director of the Clinical Research Unit, Jewish General Hospital, and co-investigator in the trial added: "It's rare that discoveries in basic research move to clinical so quickly and successfully."

The next challenge for this team is to overcome the resistance that develops over time to ribavirin. "Combination therapy with chemotherapeutic agents may enhance the efficacy of this treatment," explains Borden, "Trials in the near future are planned to overcome this and we are looking forward to more complete remissions. We also hope to test whether ribavirin is as effective in the treatment of other cancers with dysregulated eIF4E. Our laboratory studies suggest this is likely."

The study team also included Drs. Brian Leber from McMaster University/Hamilton Health Sciences (Ontario) and Denis-Claude Roy from Hpital Maisonneuve-Rosemont in Montreal. The study was made possible thanks to a $600,000 grant awarded to Dr. Borden by The Leukemia and Lymphoma Society (USA).


'/>"/>

Contact: Carolyne Lord
carolyne.lord@umontreal.ca
514-343-7282
University of Montreal
Source:Eurekalert

Related medicine news :

1. Telesso Technologies wins Popular Science Invention Award for its novel peripheral IV catheter
2. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
3. Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
4. Novel gene predicts local recurrence in early onset breast cancer
5. Novel gene predicts local recurrence in early-onset breast cancer
6. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
7. Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
8. Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development
9. Spiritual Leaders Teachings Collected in New Novel
10. Novel role of protein in generating amyloid-beta peptide
11. Novel cancer drug reduces neuroblastoma growth by 75 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology: